Computer-Aided Detection Market 2026 Growth Boosted by AI Adoption

Revenue, 2025

985.58 Million

Forecast, 2035

1640.93 Million

CAGR, 2026-2035

5.23%

Report Coverage

Global

Computer-Aided Detection Market Size, Insights and Key Players with Segment Analysis

The global computer-aided detection market size is calculated at USD 985.58 million in 2025, grew to USD 1037.13 million in 2026, and is projected to reach around USD 1640.93 million by 2035. The market is expanding at a CAGR of 5.23% between 2026 and 2035.

Key Takeaways

• Computer-aided detection market to crossed USD 1037.13 million by 2026.
• Market projected at USD 1640.93 million by 2035.
• CAGR of 5.23% expected in between 2026 to 2035.
• North America held a major revenue share of the market in 2024.
• Asia-Pacific is expected to witness the fastest growth during the predicted timeframe.
• By application, the breast cancer segment dominated the market in 2024.
• By application, the lung cancer segment is expected to expand rapidly in the computer-aided detection market in the coming years.
• By imaging modalities, the X-ray imaging segment accounted for the highest revenue share of the market in 2024.
• By imaging modalities, the computed tomography (CT) segment is expected to witness the fastest growth in the market over the forecast period.
• By end-user, the hospitals segment held a dominant revenue share of the market in 2024.
• By end-user, the diagnostic centers segment is expected to show the fastest growth over the forecast period.

Key Indicators and Highlights

The computer-aided detection market is primarily driven by the rising prevalence of chronic disorders, such as cancer, musculoskeletal disorders, and infectious diseases. Healthcare professionals leverage advanced computer tools to enhance diagnostic accuracy and reduce false negative rates. Integrating artificial intelligence (AI) in computer-aided detection (CAD) automates image identification and disease classification, thereby highlighting potential abnormalities.

Computer-Aided Detection: Revolutionizing Diagnostics

The computer-aided detection market is experiencing robust growth, driven by the rising prevalence of chronic diseases, growing demand for early diagnosis and screening, and the increasing need for personalized care. It encompasses the development, manufacturing, and supply of CAD tools and software in healthcare organizations. CAD systems assess signs of chronic diseases from radiology images, enabling healthcare professionals to make informed clinical decisions. They are used with various types of imaging systems, such as mammography, X-ray, CT, and MRI.

Computer-Aided Detection Market Outlook

• Industry Growth Overview: The market is expected to grow rapidly between 2025 and 2030, especially in low- and middle-income countries, with evolving regulatory landscapes and advancements in medical technologies. Government organizations also support the use of CAD for numerous chronic diseases.
• Sustainability Trends: Developers adopt Sustainability-by-Design principles to integrate design engineering, manufacturing processes, materials, and sustainability considerations. This enables them to evaluate trade-offs between technical performance and environmental impact.
• Major Investors: Government and private organizations provide funding to medical device startups, promoting the development of CAD software. Funding not only supports the development but also supports the deployment of advanced tools in healthcare organizations.

What is the Role of AI in the Computer-Aided Detection Market?

AI and machine learning (ML) algorithms are increasingly utilized and integrated into medical practice, assisting healthcare professionals/radiologists in the early detection of chronic diseases. They improve efficiency, diagnostic accuracy, and standardization, decreasing the workload on radiologists. AI and ML allow radiologists to focus on their core tasks, such as reporting, consultations, and direct patient interaction. They analyze vast amounts of data and assist in feature extraction and image classification.

Segmental Insights

Application Insights

Which Application Segment Dominated the Computer-Aided Detection Market?

The breast cancer segment held a dominant position in the market in 2024, due to the rising prevalence of breast cancer and the availability of licensed devices. Breast cancer is the most common cancer, especially among women, accounting for 2.3 million new cases annually. Digital mammography tools are preferred to detect and classify breast cancer lesions and identify subtle abnormalities. They can detect minute changes in the breast that are difficult to view by a human.

Lung Cancer

The lung cancer segment is expected to grow at the fastest CAGR in the computer-aided detection market during the forecast period. CAD has a highly sensitive ability to detect early lung cancer to find small nodular lesions that are missed in daily image reading. The increasing prevalence of lung cancer potentiates the need for early detection. The American Cancer Society estimated about 226,650 new lung cancer cases in the U.S. in 2025.

Colon/Rectal Cancer

The colon/rectal cancer segment is expected to show lucrative growth, driven by the increasing incidence of colorectal cancer. AI-based CAD can improve colonoscopy and can be used for screening of colorectal cancer. It is a non-invasive method for predicting deeply invasive colorectal cancer. Since colon cancer develops from precursor adenomatous polyps, early detection and removal of polyps can reduce the chance of developing cancer.

Imaging Modalities Insights

Why Did the X-Ray Imaging Segment Dominate the Computer-Aided Detection Market?

The X-ray imaging segment held the largest revenue share of the market in 2024, due to the widespread availability of X-ray tools in healthcare organizations and high affordability. X-ray systems provide accurate, rapid detection of various diseases. Advanced digital X-ray systems are designed to reduce patient radiation exposure and associated risks. The availability of portable X-ray systems also contributes to the segment’s growth. CAD results in a more streamlined, effective healthcare process, improving the quality of patient care.

Computed Tomography (CT)

The computed tomography (CT) segment is expected to grow with the highest CAGR in the computer-aided detection market during the studied years. A CT scan is one of the most advanced diagnostic tools, offering multiple benefits, such as high speed, reduced hospital stay, and improved patient placement into appropriate areas of care. AI-based CT scans help radiologists predict and detect factors that are responsible for disease progression in the near future.

Ultrasound Imaging

The ultrasound imaging segment is expected to grow in the coming years, due to higher safety, no radiation exposure, and easy operability. Portable ultrasound systems are available that can be used bedside, eliminating the need to transport patients to medical laboratories. CAD-based ultrasound imaging systems generate clearer, high-quality images, allowing providers to view hidden changes.

End-User Insights

How the Hospitals Segment Dominated the Computer-Aided Detection Market?

The hospitals segment contributed the biggest revenue share of the market in 2024, due to favorable infrastructure and increasing patient volumes. Hospitals receive funding from the government and private organizations, enabling them to adopt advanced detection tools. People prefer visiting hospitals due to favorable reimbursement policies and the presence of multidisciplinary experts.

Diagnostic Centers

The diagnostic centers segment is expected to expand rapidly in the computer-aided detection market in the coming years. Diagnostic centers possess specialized equipment for detecting numerous disorders. They have skilled professionals to provide personalized care and generate detailed reports of patients’ diagnoses. They offer an array of benefits from early detection and prevention to specialized testing and comprehensive health assessments.

Research Centers

The research centers segment is expected to grow at a notable CAGR, driven by growing research activities and increasing R&D investments. Research centers adopt advanced CAD tools and software to help researchers study the disease progression. This enables them to design novel drug candidates. CAD simplifies a researcher’s task, allowing them to focus on data interpretation.

Regional Growth

• North America dominated the global market in 2024.
• Asia-Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
• Europe is expected to grow at a considerable CAGR in the upcoming period.
• The South American particularly in Brazil, is experiencing significant growth.
• The Middle East and Africa (MEA) region presents a burgeoning market for CAD systems.

Which Factors Drive the Computer-Aided Detection Market in North America?

North America dominated the global market in 2024. The presence of a robust healthcare infrastructure, the increasing adoption of advanced technologies, and favorable regulatory support are the major factors driving market growth in North America. The growing demand for personalized care and advanced diagnostic tools propels the market. The increasing investments and collaborations contribute to market growth.

Favorable Regulatory Support Dominated the U.S.

The Food and Drug Administration (FDA) regulates the approval of CAD systems in the U.S. As of July 2025, the U.S. FDA has approved a total of 1,247 AI/ML-based medical devices. The increasing number of diagnostic laboratories also fosters the demand for CAD tools. As of 2024, there were approximately 32,828 diagnostic & medical laboratories in the U.S.

How is Asia-Pacific Growing in the Computer-Aided Detection Market?

Asia-Pacific is expected to grow at the fastest CAGR in the market during the forecast period. The rising prevalence of chronic disorders, the growing geriatric population, and the increasing awareness of advanced CAD tools foster market growth. The presence of key players and favorable research and clinical trial infrastructure facilitates the development of innovative CAD systems. Countries like China, India, and Japan host conferences and workshops to share the latest updates on innovative diagnostic techniques.

Increasing Awareness Fuels China’s Growth

China is set to host the 12th OMIA Workshop on MICCAI 2025 to bring together scientists, clinicians, and students from multiple disciplines to address key challenges related to the application of advanced computer vision and ML technologies. The nation is also establishing its clinical trial infrastructure to support trials on CAD. A total of 7 studies were registered in China as of November 2025.

Will Europe Grow in the Computer-Aided Detection Market?

Europe is expected to grow at a considerable CAGR in the upcoming period. Government organizations provide funding to research institutions and medical devices to support the development of CAD systems. Increasing collaborations among key players, along with public-private partnerships, foster the market. People are becoming aware of the screening and early diagnosis of several chronic disorders, potentiating the demand for CAD. The rising prevalence of chronic disorders and the burgeoning healthcare sector bolster market growth.

Government Support to Drive the UK

The Medicines and Healthcare Products Regulatory Agency (MHRA) recently established an “AI Airlock programme” to support the manufacturing of AI-powered healthcare technologies. The NHS England invested nearly £6 million to facilitate the development of AIR-SP, an AI screening platform, to help expedite diagnosis.

South America CAD Expansion

The South American Computer-Aided Detection market, particularly in Brazil, is experiencing significant growth. This upward trend is primarily driven by the increasing incidence of chronic diseases like cancer. The region is actively adopting AI-powered diagnostic tools to enhance early detection and improve patient outcomes across healthcare facilities.

Brazil Leading Digital Diagnostics

Brazil remains a key driver in the South American CAD market. Government and private sector initiatives are increasingly focusing on preventive healthcare and screening programs. This is boosting the adoption of advanced imaging solutions, specifically those for breast and lung cancer detection, pushing market value higher.

MEA Modernizing Healthcare Rapidly

The Middle East and Africa (MEA) region presents a burgeoning market for CAD systems. Growth is supported by substantial government investments aimed at modernizing healthcare infrastructure. Rising awareness about early diagnosis and the increasing availability of sophisticated diagnostic imaging technologies contribute to market expansion across the region.

GCC Adopting Artificial Intelligence

GCC countries are at the forefront of CAD adoption in the MEA, showing a strong focus on artificial intelligence integration. National digital transformation strategies and high per capita healthcare spending are major growth factors. The demand for advanced diagnostic accuracy in oncology and other critical areas fuels this rapid market growth.

Which Top Companies Are Leading the Computer-Aided Detection (CAD) Market in 2025?

• DeepTek AI
• Delft Imaging
• VinBrain
• Infervision
• JLK Group
• Qure.ai
• Kromek Group
• Dassault Systèmes
• Align Technology, Inc.

Top Companies & Their Offerings in the Computer-Aided Detection Market

Hologic, Inc.

Company Overview:

• A global medical technology innovator primarily focused on women's health, offering detection, diagnostic, and surgical solutions.
• CAD Focus: A market leader in Computer-Aided Detection systems for breast health, particularly Digital Breast Tomosynthesis (3D Mammography).

Corporate Information:

• Headquarters: Marlborough, Massachusetts, U.S.
• Year Founded: 1985
• Ownership Type: Public (NASDAQ: HOLX), Awaiting Acquisition: Announced a definitive agreement on October 21, 2025, to be acquired by funds managed by Blackstone and TPG for up to $$79$ per share.

History and Background:

• Began with a focus on bone densitometry and rapidly expanded its portfolio through strategic acquisitions and internal innovation in the women's health diagnostic and surgical space.
• Established leadership in mammography and breast imaging with the introduction of 3D mammography systems.

Key Milestones/Timeline:

• November 2024: Launched the Envision Mammography Platform at RSNA, offering an advanced 3D mammogram with a fast scan time of 2.5 seconds.
• July 2024: Completed the acquisition of Endomagnetics, expanding its localization and tracing product portfolio within Breast Health.
• October 2025: Announced agreement to be acquired by Blackstone and TPG.

Business Overview:

• Develops, manufactures, and supplies high-performance diagnostic and surgical products, with a core mission centered on The Science of Sure$^{text{textregistered}}$ to deliver certainty in healthcare.
• FY 2025 Revenue (TTM as of 09/30/2025): $$4.1$ Billion (Source: PitchBook).

Business Segments/Divisions:

• Diagnostics (Largest segment by revenue, $sim44$% of total sales in FY 2025): Molecular Diagnostics, Cytology, and Perinatal.
• Breast Health ($sim38$% of total sales in FY 2025): Includes Mammography (2D and 3D systems with CAD/AI, Biopsy, and Breast Surgery solutions).
• Surgical ($sim16$% of total sales in FY 2025): Minimally invasive gynecological surgery products.
• Skeletal Health ($sim2$% of total sales in FY 2025).

Geographic Presence:

Global operations, with the U.S. accounting for the largest portion of revenue ($sim69%)$, followed by Europe ($ sim20%$)$, and Asia ($sim8%$).

Key Offerings (CAD/AI):

• Genius AI$^{text{TM}}$ Detection: CAD software designed to support radiologists by improving the accuracy and consistency of breast cancer detection, optimized for 3D mammography (Digital Breast Tomosynthesis or DBT).
• 3DQuorum$^{text{TM}}$ Technology: CAD feature that generates a synthesized 3D image, reducing the number of 3D slices needing review by radiologists.
• Clarity HD High-Resolution Imaging.

End-Use Industries Served:

• Hospitals and Healthcare Systems.
• Diagnostic and Imaging Centers.
• Physician’s Offices and Clinics.

Key Developments and Strategic Initiatives:

Mergers & Acquisitions:

• July 2024: Acquired Endomagnetics to enhance its breast-conserving surgery portfolio.
• September 2025: Made a Later Stage VC investment in Mercy BioAnalytics.
• February 2024: Made a Later Stage VC investment in Whiterabbit.ai (AI breast imaging).

Partnerships & Collaborations

Continues collaboration with organizations like the WTA (Women’s Tennis Association) to promote women's health awareness.

Product Launches/Innovations:

November 2024: Launched the Envision Mammography Platform with a 2.5-second scan time for 3D mammograms.

Capacity Expansions/Investments:

Ongoing significant R&D investment, contributing to a $sim4.8%$ Compound Annual Growth Rate (CAGR) in total sales over the decade leading up to 2024.

Regulatory Approvals:

• October 2025: Received FDA Clearance and CE Mark for automated molecular tests to detect common causes of infectious gastroenteritis, expanding its diagnostic assay menu.
• November 2025: Introduced Digital Pathology capabilities with expanded CE Marking.
• Distribution channel strategy: Direct sales organization and distribution partners globally.

Technological Capabilities/R&D Focus:

• Core Technologies/Patents: Holds over 3,200 total patent documents (applications and grants). Focus on AI, 3D imaging, molecular diagnostics, and minimally invasive surgery.
• Research & Development Infrastructure: Substantial commitment to R&D innovation across all business segments.
• Innovation Focus Areas: AI-powered diagnostic tools to reduce reading times and improve accuracy; expansion of the molecular diagnostics assay menu on the Panther system; next-generation 3D breast imaging.

Competitive Positioning:

Strengths & Differentiators: Strong global installed base in breast health, robust recurring revenue from diagnostic assays, deep integration of proprietary AI (Genius AI) into its 3D mammography platform, and a comprehensive portfolio focused on women's health.

Market presence & ecosystem role: Leader in the global breast imaging market; its Panther molecular system is a core driver in the Diagnostics segment.

SWOT Analysis:

• Strengths: Market leadership in breast CAD/3D Mammography; strong, diversified portfolio; high recurring revenue base; consistent long-term sales growth.
• Weaknesses: High cost of advanced equipment potentially limiting adoption in some emerging markets; cybersecurity concerns with cloud-based AI.
• Opportunities: Global market penetration for AI-driven 3D mammography; expansion of AI solutions into other imaging modalities (e.g., pathology); leveraging the large private equity investment from Blackstone and TPG to accelerate growth.
• Threats: Intense competition from large imaging conglomerates (GE, Siemens, Philips) and niche AI startups; regulatory changes in global healthcare.

Recent News and Updates:

Press Releases:

• October 21, 2025: Hologic to be Acquired by Blackstone and TPG for up to $$79$ per Share (Total value up to $$18.3$ billion).
• November 03, 2025: Announced financial results for Q4 fiscal 2025, with revenue of $$1,049.5$ million, growing 6.2%.

Industry Recognitions/Awards:

Included in the Dow Jones Sustainability North America Composite Index in the past, reflecting strong ESG performance.

iCAD, Inc.

Company Overview:

• A medical technology company specializing in AI-powered cancer detection and risk assessment solutions.
• CAD Focus: A key specialized vendor offering high-performance, Artificial Intelligence (AI) and Computer-Aided Detection (CAD) systems, primarily for 2D and 3D mammography.

Corporate Information:

• Headquarters: Nashua, New Hampshire, U.S.
• Year Founded: 1984
• Ownership Type: Public (NASDAQ: ICAD), Acquired: Announced acquisition by RadNet Inc. in July 2025.

History and Background:

• Founded to provide image analysis and workflow solutions for early cancer detection.
• Transitioned from being a pure CAD company to a leader in AI-driven breast health solutions, particularly with its flagship ProFound AI$^{text{textregistered}}$ platform.

Key Milestones/Timeline:

• H1 2023: Completed Xoft divestiture to focus solely on the Detection business.
• Q2 2024: Reported Total Annual Recurring Revenue (T-ARR) of $$9.2$ million.
• July 2025: Acquired by RadNet Inc., a provider of diagnostic imaging services.

Business Overview:

• Focuses exclusively on its Detection business segment, which provides image analysis and workflow solutions, leveraging deep learning AI for breast cancer detection and risk assessment.
• Revenue (2024): Approximately $$19.6$ million (Source: GlobalData).

Business Segments/Divisions:

Detection: Includes AI-powered CAD and workflow solutions for breast and other cancers, utilizing the ProFound AI suite. (Post-2023 divestiture of the Xoft therapy business, this is the sole focus.)

Geographic Presence:

• Markets products globally in over 50 countries through direct sales, OEM partners (e.g., GE HealthCare), distributors, and resellers.
• Operates in the U.S. and key European markets (France, Belgium, Italy, Germany, Switzerland).

Key Offerings (CAD/AI):

ProFound Suite:

• ProFound AI Detection: Deep learning CAD for 2D and 3D (DBT) mammography, designed to rapidly analyze images and provide key metrics to radiologists, reducing reading time by an estimated $sim50%$.
• ProFound AI Risk: Provides personalized, short-term breast cancer risk assessment in real-time.
• ProFound Density: Automated breast density assessment.

End-Use Industries Served:

• Diagnostic and Breast Imaging Centers.
• Hospitals and Healthcare Systems.
• Teleradiology service providers.

Key Developments and Strategic Initiatives:

Mergers & Acquisitions:

July 2025: Acquired by RadNet Inc.

Partnerships & Collaborations:

• Signed 20-year partnership with Google Health.
• First AI solution to be offered in GE HealthCare's MyBreastAI Suite.
• July 2024: Entered agreement with Windsong Radiology to implement AI-powered mammography.
• April 2024: Entered agreement with Densitas Inc. for breast cancer screening.

Product Launches/Innovations:

Continued enhancement of the ProFound AI platform with new features like Heart Health applications (currently not available in all geographies).

Capacity Expansions/Investments:

Focusing on expanding its AI solutions via a strong direct and indirect channel strategy.

Regulatory Approvals:

• ProFound AI Detection: FDA Cleared, CE Marked, and Health Canada Licensed.
• ProFound AI Risk: CE Marked (MDD) and Health Canada Licensed.
• Distribution channel strategy: Mix of direct sales, OEM partnerships (e.g., GE), distributors, and resellers.

Technological Capabilities/R&D Focus:

• Core Technologies/Patents: Focus on AI-powered image analysis and workflow solutions; holds over 200 total patent documents.
• Key Patent: System and method for assessing breast cancer risk using imagery.
• Research & Development Infrastructure: Leveraging its partnership with Google Health for R&D. Trained its deep learning models on a global data set of over $6$ million diverse images from $100+$ global centers.
• Innovation Focus Areas: AI-driven risk assessment (ProFound AI Risk) and expanding AI applications beyond breast cancer detection to include cardiovascular health.

Competitive Positioning:

• Strengths & Differentiators: Specialized focus on high-performance breast CAD/AI, leading ProFound AI platform with proven clinical evidence (e.g., $23%$ relative increase in cancer detection without increasing recalls), strong OEM partnerships (GE), and a highly diversified training data set.
• Market presence & ecosystem role: A specialized leader in the breast AI market, often integrated into the hardware of major imaging vendors.

SWOT Analysis:

• Strengths: Deep specialization in AI breast detection, highly-rated flagship product (ProFound AI), strategic 20-year R&D partnership with Google Health, and significant recurring revenue growth (16% CAGR in T-ARR).
• Weaknesses: Smaller company revenue and market capitalization compared to conglomerate competitors; heavy reliance on a single product suite (ProFound AI).
• Opportunities: Expansion of AI risk assessment and density solutions; leveraging the financial and customer base of its new parent company, RadNet, Inc.; growth in the underpenetrated U.S. AI mammography market ($sim63%$ unpenetrated).
• Threats: Competitive pressure from major imaging OEMs developing in-house AI solutions and other emerging AI startups; integration challenges post-acquisition.

Recent News and Updates:

Press Releases:

The latest focus is on the successful execution of the management-led transformation plan, leading to significantly reduced cash burn (Q2 2024).

Industry Recognitions/Awards:

Cited in multiple clinical studies for the performance of its ProFound AI platform, demonstrating enhanced clinical performance compared to other platforms.

Recent Developments in the Computer-Aided Detection Market

• In June 2025, the World Health Organization (WHO) approved 6 new software products for use in the CAD of tuberculosis on chest X-rays during TB screening. The approval was made based on an independent evaluation by the Technical Advisory Group on Tuberculosis Diagnostics and Laboratory Strengthening. The WHO has recommended the use of CAD for TB screening since 2021.
• In March 2025, Align Technology, Inc. announced the launch of Align X-ray Insights, a new software-based CADe solution, in the European Union countries and the UK. The platform leverages AI to automatically analyze 2D radiographs to diagnose dental and oral conditions, standardizing analysis, streamlining workflows, and improving patient engagement.

Segments Covered in the Report

By Application

• Breast Cancer
• Lung Cancer
• Colon/Rectal Cancer
• Prostate Cancer
• Liver Cancer
• Bone Cancer
• Neurological/Musculoskeletal/Cardiovascular Cancer

By Imaging Modalities

• X-Ray Imaging
• Computed Tomography (CT)
• Ultrasound Imaging
• Tomosynthesis
• Nuclear Imaging

By End-User

• Hospitals
• Diagnostic Centers
• Research Centers

By Region

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe
  • Western Europe
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
• Eastern Europe
  • Austria
  • Russia & Belarus
  • Turkiye
  • Albania
  • Rest of Eastern Europe
• Asia Pacific (APAC)
  • China
  • Taiwan
  • India
  • Japan
  • Australia & New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• Middle East and Africa (MEA)
  • GCC Countries
  • Saudi Arabia
  • United Arab Emirates (UAE)
  • Qatar
  • Kuwait
  • Oman
  • Bahrain
• South Africa
• Egypt
• Rest of MEA